A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

Multispecialty Aesthetic Clinical Research Organization

Status and phase: Unknown; Phase 2

Conditions: Senile Purpura

Treatments: Drug: adapalene gel 0.3%

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01485367

AD3001

Details and patient eligibility

About

This is an open label 6 month pilot study for male and female participants over the age of 52 that desire treatment and prevention of senile purpura of the forearms.

This study will be evaluating the effects of Adapalene 0.3% for the use in the treatment and prevention of senile purpura.

Full description

This is a new potential use for the product Adapalene 0.3%, which is currently an FDA approved topical treatment used for the treatment of acne.

Senile purpura is a common sign of aging that appears in the form of dark blotches on the skin and is caused by bruising.

Older adults tend to be more prone to bruising, since as people age, their skin becomes thinner and more fragile.

Enrollment: 20 estimated patients

Sex: All

Ages: 52+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female over 52 years of age with signs of senile purpura on either the right or left (or both) dorsal hand & extensor forearm and desire treatment for this condition that is associated with aging.
• Women who have had hysterectomies, tubal ligations or who are post-menopausal for at least one year prior to the study may be enrolled. Women of childbearing potential who are not pregnant, not planning to become pregnant during the study period, and not lactating may be enrolled if they are using a medically accepted contraceptive program initiated at least one month prior to study entry and continued during the study.
• Subject is willing to comply with study instructions and return to the clinic for required visits.
• Subject is able to understand and has signed an IRB approved informed consent form including consent for photography.

Exclusion criteria

• All subjects on coumadin, heparin, plavix, supplemental herbs, vitamin E, empirin, fiorinal, norgesic, forte, percodan, robaxin, nuprin, ansaid, anaprox, clinoril, dolobid, feldene, naprosyn, voltaren, fish oil, oral steroids, or daily use of aspirin, Motrin, or Advil. (PRN usage not excluded)
• Prior treatment with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids within 3 months of study enrollment is prohibited.
• Clotting abnormalities as determined by screening labs
• Any history of a stroke or unstable heart disease
• Participation in another clinical trial with exposure to any investigational agent within 30 days prior to Screening Visit.
• Any condition the Investigator believes would interfere with subject's ability to provide informed consent, comply with study instruction, or which might confound the interpretation of the study results or put the subject at undue risk.
• Subject is pregnant, breastfeeding or planning a pregnancy during the study.
• Subject is unable to communicate or cooperate with the Investigator due to a language barrier (non-English speaking).
• Subjects who are allergic to adapalene or the ingredients in the gel.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Adapalene gel 0.3%

Active Comparator group

Description:

All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.

Treatment:

Drug: adapalene gel 0.3%

Adapalene gel 0.3 %

Active Comparator group

Description:

All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.

Treatment:

Drug: adapalene gel 0.3%